| 1 |
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Steven E. Nissen et al. · New England Journal of Medicine
Open access |
4 Mar 2023 |
951 |
| 2 |
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik Kumar Ray, Harold Edward Bays, Alberico Luigi Catapano et al. · New England Journal of Medicine
Open access |
13 Mar 2019 |
815 |
| 3 |
Aromaticity as a Cornerstone of Heterocyclic Chemistry
Alexandrù T. Balaban, Daniela Carmen Oniciu, ALAN ROY KATRITZKY · Chemical Reviews
Review |
17 Apr 2004 |
812 |
| 4 |
Methionine‐deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF‐I and insulin levels, and increases hepatocyte MIF levels and stress resistance
Richard A. Miller, Gretchen Buehner, Yayi Chang et al. · Aging Cell
Open access |
13 Apr 2005 |
755 |
| 5 |
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Stephen L. Pinkosky, Roger S. Newton, Emily Anne Day et al. · Nature Communications
Open access |
28 Nov 2016 |
498 |
| 6 |
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
Anne Carol Goldberg, Lawrence A. Leiter, Erik S.G. Stroes et al. · JAMA
Open access |
12 Nov 2019 |
486 |
| 7 |
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Ulrich Laufs, Maciej Banach, G.B. John Mancini et al. · Journal of the American Heart Association
Open access |
29 Mar 2019 |
443 |
| 8 |
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie Mitchell Ballantyne, Maciej Banach, G.B. John Mancini et al. · Atherosclerosis
Open access |
12 Jun 2018 |
430 |
| 9 |
Lipogenesis inhibitors: therapeutic opportunities and challenges
Battsetseg Batchuluun, Stephen L. Pinkosky, Gregory R. Steinberg · Nature Reviews Drug Discovery
ReviewOpen access |
14 Jan 2022 |
407 |
| 10 |
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
Christie Mitchell Ballantyne, Ulrich Laufs, Kausik Kumar Ray et al. · European Journal of Preventive Cardiology
Open access |
29 Jul 2019 |
367 |
| 11 |
Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
Maria-Corina Șerban, Lisandro Damián Colantonio, Angelika D. Manthripragada et al. · Journal of the American College of Cardiology
Open access |
Mar 2017 |
321 |
| 12 |
Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant
Cesare Riccardo Sirtori, Laura Calabresi, Guido Franceschini et al. · Circulation
Open access |
17 Apr 2001 |
320 |
| 13 |
Quantitative Measures of Aromaticity for Mono-, Bi-, and Tricyclic Penta- and Hexaatomic Heteroaromatic Ring Systems and Their Interrelationships
ALAN ROY KATRITZKY, Karl Jug, Daniela Carmen Oniciu · Chemical Reviews
Review |
20 Apr 2001 |
306 |
| 14 |
AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases
Rai Ajit K. Srivastava, Stephen L. Pinkosky, Sergey Ivanovich Filippov et al. · Journal of Lipid Research
Open access |
14 Jul 2012 |
299 |
| 15 |
Metabolomics applications of FT‐ICR mass spectrometry
Stephen C. Brown, Gary H. Kruppa, Jean‐Louis Dasseux · Mass Spectrometry Reviews
|
30 Mar 2004 |
285 |
| 16 |
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
Stephen L. Pinkosky, Sergey Ivanovich Filippov, Rai Ajit K. Srivastava et al. · Journal of Lipid Research
Open access |
3 Nov 2012 |
241 |
| 17 |
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
Per Albertsson, Per H. Basse, Marianne Hokland et al. · Trends in Immunology
Review |
11 Oct 2003 |
226 |
| 18 |
Increased Atherosclerosis in ApoE and LDL Receptor Gene Knock-Out Mice as a Result of Human Cholesteryl Ester Transfer Protein Transgene Expression
Andrew S. Plump, Lori Masucci-Magoulas, Can Bruce et al. · Arteriosclerosis Thrombosis and Vascular Biology
|
Apr 1999 |
224 |
| 19 |
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Marisa R. Morrow et al. · Cell Metabolism
Open access |
Jun 2022 |
196 |
| 20 |
Recombinant Apolipoprotein A-I Milano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks
Giulia Chiesa, Elena Monteggia, Marta Marchesi et al. · Circulation Research
Open access |
17 May 2002 |
196 |
| 21 |
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach, Paul Barton Duell, Antonio M. Gotto et al. · JAMA Cardiology
Open access |
Jul 2020 |
193 |
| 22 |
Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia
Christie Mitchell Ballantyne, Michael H. Davidson, Diane Elaine MacDougall et al. · Journal of the American College of Cardiology
Open access |
13 Jun 2013 |
179 |
| 23 |
Mouse Macrophage Paraoxonase 2 Activity Is Increased Whereas Cellular Paraoxonase 3 Activity Is Decreased Under Oxidative Stress
Mira Rosenblat, Dragomir Ivanov Draganov, Catherine E. Watson et al. · Arteriosclerosis Thrombosis and Vascular Biology
|
Mar 2003 |
167 |
| 24 |
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
Paul D. Thompson, John Rubino, Matthew James Janik et al. · Journal of clinical lipidology
Open access |
29 Mar 2015 |
165 |
| 25 |
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance
Paul Daniel Thompson, Diane Elaine MacDougall, Roger S. Newton et al. · Journal of clinical lipidology
Open access |
6 Jan 2016 |
147 |
| 26 |
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Steven E. Nissen, Venu Menon, Stephen James Nicholls et al. · JAMA
Open access |
24 Jun 2023 |
145 |
| 27 |
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance
Paul M. Ridker, Lei Lei, Michael J. Louie et al. · Circulation
Open access |
6 Nov 2023 |
144 |
| 28 |
Evidence that MIG-6 is a tumor-suppressor gene
Y-W Zhang, Ben Staal, Yingchun Su et al. · Oncogene
|
3 Jul 2006 |
142 |
| 29 |
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
StephenJ Nicholls, A. Michael Lincoff, Harold Edward Bays et al. · American Heart Journal
Open access |
23 Oct 2020 |
139 |
| 30 |
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults
Martin Markowitz, Andrew R. Zolopa, K. Squires et al. · Journal of Antimicrobial Chemotherapy
|
6 Feb 2014 |
129 |
| 31 |
Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy
Christie Mitchell Ballantyne, James M. McKenney, Diane Elaine MacDougall et al. · The American Journal of Cardiology
Open access |
6 Apr 2016 |
128 |
| 32 |
T Cell Responses in Mammalian Diaphanous-related Formin mDia1 Knock-out Mice
Kathryn M. Eisenmann, Richard A. West, Dagmar Hildebrand et al. · Journal of Biological Chemistry
Open access |
27 Jun 2007 |
123 |
| 33 |
Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
Stephen L. Pinkosky, Pieter H.E. Groot, Narendra D. Lalwani et al. · Trends in Molecular Medicine
Review |
12 Oct 2017 |
119 |
| 34 |
Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins
Shucun Qin, Koichi Kawano, Can Bruce et al. · Journal of Lipid Research
Open access |
Feb 2000 |
111 |
| 35 |
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Harold Edward Bays, Maciej Banach, Alberico Luigi Catapano et al. · Journal of clinical lipidology
Open access |
Sep 2020 |
105 |
| 36 |
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr −/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid
Joshua P Samsoondar, Amy C. Burke, Brian G. Sutherland et al. · Arteriosclerosis Thrombosis and Vascular Biology
Open access |
3 Feb 2017 |
98 |
| 37 |
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
José Baselga, Alexey Manikhas, Javier Cortés et al. · Annals of Oncology
Open access |
9 Jan 2014 |
98 |
| 38 |
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Kausik Kumar Ray, Stephen James Nicholls, Na Li et al. · The Lancet Diabetes & Endocrinology
Open access |
4 Dec 2023 |
97 |
| 39 |
Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
Rai Ajit K. Srivastava, Ravi Jahagirdar, Salman Azhar et al. · Molecular and Cellular Biochemistry
|
13 Feb 2006 |
97 |
| 40 |
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
John Rubino, Diane Elaine MacDougall, Lulu Ren Sterling et al. · Atherosclerosis
|
30 Dec 2020 |
95 |
| 41 |
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease
Yu-Wen Zhang, Yanli Su, Nathan James Lanning et al. · Proceedings of the National Academy of Sciences
Open access |
8 Aug 2005 |
95 |
| 42 |
Evidence-based goals in LDL-C reduction
Handrean Soran, Ricardo E. Dent, Paul N. Durrington · Clinical Research in Cardiology
Open access |
25 Jan 2017 |
93 |
| 43 |
Myeloproliferative Defects following Targeting of the Drf1 Gene Encoding the Mammalian Diaphanous–Related Formin mDia1
Jun Peng, Susan M. Kitchen, Richard A. West et al. · Cancer Research
|
15 Aug 2007 |
92 |
| 44 |
ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
Sergey Ivanovich Filippov, Stephen L. Pinkosky, Richard J. Lister et al. · Journal of Lipid Research
Open access |
25 May 2013 |
92 |
| 45 |
Dose-Related Effects of Repeated ETC-216 (Recombinant Apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl Phosphatidylcholine Complexes) Administrations on Rabbit Lipid-Rich Soft Plaques
Cinzia Parolini, Marta Marchesi, Paolo Lorenzon et al. · Journal of the American College of Cardiology
Open access |
Mar 2008 |
90 |
| 46 |
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial
Narendra D. Lalwani, Jeffrey Christian Hanselman, Diane Elaine MacDougall et al. · Journal of clinical lipidology
|
13 May 2019 |
79 |
| 47 |
Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome
Clay T. Cramer, Brian D. Goetz, Krista L. Hopson et al. · Journal of Lipid Research
Open access |
8 Jun 2004 |
74 |
| 48 |
Intramural Delivery of Recombinant Apolipoprotein A-I Milano /Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries
Sanjay Kaul, Vladimir Rukshin, Raul Santos et al. · Circulation
|
13 May 2003 |
74 |
| 49 |
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial
John Rubino, Diane Elaine MacDougall, Lulu Ren Sterling et al. · Journal of clinical lipidology
Open access |
28 May 2021 |
72 |
| 50 |
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial
Paul M. Ridker, Lei Lei, Kausik Kumar Ray et al. · Journal of clinical lipidology
|
14 Feb 2023 |
71 |